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Benefits of ERAS protocol have been well documented; however, it is unclear whether the improvement stems from the protocol or
shifts in expectations. Interdisciplinary educational seminars were conducted for all health professionals. However, one test surgeon
adopted the protocol. 394 patients undergoing elective abdominal surgery from June 2013 toApril 2015with amedian age of 63 years
were included. The implementation of ERAS protocol resulted in a decrease in the length of stay (LOS) and mortality, whereas the
difference in cost was found to be insignificant. For the test surgeon, ERAS was associated with decreased LOS, cost, and mortality.
For the control providers, the LOS, cost, mortality, readmission rates, and complications remained similar both before and after the
implementation of ERAS. An ERAS protocol on the single high-volume surgical unit decreased the cost, LOS, and mortality.
1. Introduction
The concept of enhanced recovery after surgery (ERAS)
involves the integration of evidence-based medicine into
clinical practice to improve patient outcomes.The application
of new evidence is often delayed and inconsistently adapted
into clinical care [1–3].The genesis of ERAS is associated with
the colonic surgeries of the 1990s and is often attributed to
Professor Henrik Kehlet of Copenhagen [4]. Kehlet reported
length of stays (LOS) of 2-3 days for patients undergoing
colonic surgery in an era when LOS was typically more
than 9 days. The term ERAS was coined in 2001 by a group
of academic surgeons in Europe working on protocols for
colon surgery [5], who were heavily influenced by Kehlet’s
remarkable results.
The basic tenets of ERAS include the adoption of
evidence-based practices to decrease surgical stress, maintain
physiologic homeostasis, and facilitate recovery of patients
[6, 7]. Although individual componentsmay vary,most of the
ERAS programs include avoidance of fasting, optimization
of health, preoperative carbohydrate loading, avoidance of
bowel preparation, goal-directed resuscitation, multimodal
analgesia with avoidance of opiates, avoidance/early removal
of tubes (nasogastric tube, Foley catheter, and drains), sup-
port of gastrointestinal function, and early convalescence
[4, 7, 8]. When these principles are applied to the patients
undergoing colonic surgery, factors such as LOS, complica-
tions, and readmission rates are noted to have decreased [8–
10]. Improved outcomes with ERAS implementation in colon
surgery have been documented in randomized controlled
trials and structured nationwide programs [11, 12].
The majority of data on ERAS focus on colon surgeries,
and its success has encouraged expansion to other major
abdominal operations. In a study, Joliat et al. noted a decrease
in LOS and cost after pancreaticoduodenectomy with an
ERAS program [13]. In a systematic review andmeta-analysis
of nine trials (twowere randomized controlled), Hughes et al.
reported that ERAS protocols were associated with decreased
morbidity and LOS after hepatic resection [14]. Similar results
have been reported in cases of bladder, esophagus, gastric,
Hindawi Publishing Corporation
Surgery Research and Practice
Volume 2016, Article ID 6830260, 9 pages
http://dx.doi.org/10.1155/2016/6830260
2 Surgery Research and Practice
Table 1: ERAS protocol.
Preoperative factors
High protein diet Starting at appointment date Up to 1 gr/kg, protein/day
Immunonutrition Five days prior to surgery Ensure complete liquid 1 can BID, Juben power BID
Clear liquids only After midnight on day prior to surgery Gatorade lemon-lime 20Oz, no cream, no red drinks
Last intake Three hours prior to surgery Gatorade lemon-lime 20Oz
Intraoperative factors
Pain control Throughout the case Epidural (optional), gabapentin 600mg once
Normothermia Throughout the case Bair Huger
Fluid resuscitation Throughout the case Lidco monitor
Postoperative factors
Pain control Throughout postoperative time Avoid narcotic use, gabapentin 600mg PO q 8 hrs × 3,Toradol 15mg IV q 6 hrs × 4, Tylenol 1,000 iv as needed
Bowel regimen Until return of bowel function Colace 100mg PO q 12 hrs, Dulcolax suppository 10mgPR q 24 hrs
Diet Early enteral nutrition Immunonutrition × 5 days, diet as tolerated on POD1
Early convalescence Postop day 0 Up to chair 6–8 hrs, ambulation in the halls 5 times aday
Drain management Postop days 0-1 NGT removed on postoperative days 0-1
bariatric, gynecologic, and emergent surgeries that have
implemented the ERAS protocols [15–25].
To better understand the application of ERAS protocol
in a diverse patient population and the influence of shifting
expectations on non-ERAS patients, we reviewed a pilot
program involving a single gastrointestinal oncology surgeon
on a closed surgical oncology unit. Our hypothesis was that
a single protocol encompassing the tenets of ERAS when
applied to a myriad of complex abdominal procedures would
improve the patient outcomes. In addition, we also hypothe-
sized that education of perioperative staff and changes in the
postoperative expectations would improve the outcomes in
the unit’s control (non-ERAS) population.
2. Methods
2.1. Data Source. Patients undergoing only elective abdom-
inal surgeries from June 2013 until April 2015 at Vidant
Medical Center, East Carolina University, Greenville, North
Carolina, were included in this study. Patients of three
attending surgical oncologists were retrospectively identified
from the University Health Consortium (UHC) database
using the primary procedure codes. Patients who underwent
emergent or urgent procedures were excluded. All patients
undergoing minor nonabdominal or abdominal procedures
were also excluded. The excluded abdominal procedures
included soft tissue excision, open liver biopsy, closed liver
biopsy, and excision of lymph nodes. The demographics,
operative factors, and weighted financial data of the patients
were collected. The electronic health record was utilized for
data that was unclear in the UHC dataset or was unavailable.
The age-adjustedCharlsonComorbidity Index (CCI)was cal-
culated for each patient using comorbidities within the UHC
dataset and ICD-9 codes.Then the patients were divided into
three subcategories based on their CCI score: low, with CCI
scores of 1-2; intermediate, with CCI scores of 3–5; and high,
with CCI scores of >5. The surgical procedures were divided
into six subcategories: pancreatectomy, intestinal resection,
hepatic resection, colostomy, gastrectomy, and other major
abdominal surgeries. The LOS, in-hospital mortality, read-
mission within 30 days, and postoperative complications
were recorded. The Clavien-Dindo score was utilized to
classify postoperative complications. All costs during the
index admission period were calculated using the adjusted
financial data within the UHC dataset.
2.2. Implementation of Protocol. A protocol was developed
that utilized the published guidelines by the ERAS Society for
pancreatic, colonic, and rectal/pelvic surgeries [26, 27]. The
goal was to develop a single perioperative process that could
be applied to a diverse group of patients. Protocol compo-
nents included preoperative immunonutrition, clear liquids
until 2 hours before surgery, carbohydrate loading until 2-3
hours before surgery, epidural catheter offered to all patients
undergoing laparotomy, loading dose of gabapentin, intra-
operative goal-directed resuscitation with LIDCO monitor
(LIDCO Ltd., London, UK), maintenance of normothermia,
multimodal pain management with avoidance of narcotics,
avoidance of nasogastric tubes, early removal of drains,
perioperative bowel regiment, postoperative immunonutri-
tion, and early aggressive convalescence (Table 1).
As controversies existed around the impact of enhanced
recovery programs versus shifting expectations, patients from
a single health care provider were used for tests of change;
however, educational interventions included all the staff
members. Educational interventions targeted anesthesiolo-
gists and anesthetists, dieticians, postoperative nursing staffs,
preoperative nursing staffs, and surgical residents. Multiple
educational conferences were delivered to the aforemen-
tioned key stakeholder groups involved in the health care
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program for patients at a single and closed surgical oncology
unit. In addition, the surgeon, clinical nursing staffs, and a
registered dietitian performed patient education during the
preoperative visit. Patients were also provided with written
instructions. The ERAS protocol was implemented on the
patients from a single provider in June 2014 (test surgeon)
whereas the patients from other health care providers served
as the internal control individuals.
Logistic regression was undertaken to determine differ-
ences between patients included in the ERAS protocol (test
surgeon after 2014) versus thosemanaged without ERAS (test
surgeon before 2014 and control surgeons). ERAS outcomes
were also analyzed for the test surgeon, comparing patients
before and after protocol implementation. Lastly differences
in outcomes were evaluated for the control surgeons before
and after implementation of protocol by the test surgeon in
2014.
2.3. Statistical Analysis. Patient demographics, in addition
to their operative and financial variables, were represented
as means or medians as necessary. Student’s 𝑡-test and chi-
square test were performed for univariate analysis. Variables,
having a 𝑝 value < 0.2 in univariate analysis, were included
in all multivariate models. A 𝑝 value < 0.05 was defined as
statistically significant. The analysis was conducted by using
JMP Pro Version 10.0.0 (SAS Institute Incorporated, Cary,
North Carolina, USA, 2012).
3. Results
3.1. Demographics. A total of 394 patients met the inclusion
criteria and were included in this study. The mean age of the
included patients was 62.3 years (Table 2). The patients were
evenly distributed between genders, and white was found
to be the most common racial category (59.9%). A majority
of the patients were diagnosed with colorectal, pancreatic,
hepatic (primary or secondary), gastric, or small bowel
cancer. In addition, most of the patients had low (40.4%)
or intermediate (39.6%) CCI scores. The most common
surgical procedure was other abdominal procedure followed
by pancreatectomy, intestinal resection, colectomy, hepatic
resection, and gastrectomy surgeries. Two surgeons, the
test surgeon and a second surgical oncologist, performed a
majority of the procedures. The mean and median values of
LOSwere 6 and 7.6 days, respectively, and themedian hospital
cost was $20,998. The in-hospital mortality rate was 2.3%.
3.2. ERAS versus Non-ERAS. In order to understand the
implications of the ERAS program, we divided the patients
into ERAS and non-ERAS groups (Table 3). We found that
patients were similar in gender, age, race, diagnosis, comor-
bidities, and surgical procedures in both groups. There was a
decrease of 2 days in mean LOS (𝑝 = 0.016). The in-hospital
mortality was also significantly lower in the ERAS group
(0 versus 2.9%, 𝑝 = 0.033). Cost ($18,716 versus $21,294)
and readmission rates (16 versus 11.5%) were higher for non-
ERAS patients, but these differences did not reach statistical
significance (𝑝 = 0.60 and 0.21, resp.).The complication rates
were similar.














Other abdominal 33.0 127
Colorectal cancer 28.1 108
Pancreatic cancer 15.8 61
Liver malignancies 10.1 39
Gastric cancer 6.5 25
Small bowel cancer 6.5 25
Charlson index
0–2 (low) 40.4 159
3–5 (intermediate) 39.6 156
>5 (high) 20.0 79
Surgery
Other abdominal 24.1 95
Pancreatectomy 21.1 83
Intestinal resection 18.3 72




Test physician 45.4 179
Control physician 1 44.9 177











Grade 0-I 63.2 249
Grade II–V 36.8 145
Readmissions 15.7 61
Mortality rate 2.3 9
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Table 3: ERAS versus non-ERAS (control) patients on a single surgical unit, 2013–2015.
Factor ERAS% (number) Non-ERAS% (number) 𝑝 value
Gender
Male 46.0 (40) 48.9 (150) 0.63
Female 54.0 (47) 51.1 (157)
Age
Median 62 (20–93) 63 (22–88) 0.36
Mean 61.4 (13.9) 62.8 (12.6)
Race
White 62.1 (54) 59.3 (182)
0.89Black 34.5 (30) 37.1 (114)
Other 3.5 (3) 3.6 (11)
Diagnosis
Gastric cancer 4.8 (4) 7.0 (21)
0.45
Small bowel cancer 8.4 (7) 6.0 (18)
Colorectal cancer 24.1 (20) 29.1 (88)
Pancreatic cancer 21.7 (18) 14.2 (43)
Primary and secondary liver malignancies 12.1 (10) 9.6 (29)
Other abdominal 28.9 (24) 34.1 (103)
Charlson index
0–2 43.7 (38) 39.4 (121)
0.763–5 36.8 (32) 40.4 (124)
>5 19.5 (17) 20.2 (62)
Surgery
Pancreatectomy 27.6 (24) 19.2 (59)
0.49
Colectomy 12.6 (11) 18.2 (56)
Hepatic resection 12.6 (11) 14.0 (43)
Gastrectomy 4.6 (4) 6.2 (19)
Intestinal resection 16.1 (14) 18.9 (58)
Other abdominal 26.4 (23) 23.5 (72)
LOS
Median 5 (1–39) 6 (1–55) 0.016
Mean 6.0 (4.9) 8.0 (7.3)
Complications
Grade 0-I 67.8 (59) 61.9 (190) 0.31
Grade II–V 32.2 (28) 38.1 (117)
Cost
Median $18,716 ($7,937–$93,804) $21,294 ($6,032–$174,537) 0.060
Mean $21,674 ($12,118) $25,994 ($20,092)
Readmissions
Readmission rate 11.5 (10) 16.9 (51) 0.21
Mortality
Mortality rate 0 (0) 2.9 (9) 0.033
4. Tests of Change in Single Provider
4.1. Enhanced Recovery versus Standard Care. Pre- and post-
ERAS outcomes were studied for the test provider (Table 4).
Patients in both the groups were similar in gender, age, race,
diagnosis, and comorbidities. Mean LOS was significantly
decreased during the post-ERAS implementation phase (9.6
days pre-ERAS versus 6.2 days post-ERAS, 𝑝 = 0.024). Costs
were also significantly different ($21,674 versus $30,380; 𝑝 =
0.029). The in-hospital mortality rate was also lower in the
post-ERAS phase (0 versus 3.3%, 𝑝 = 0.044). The increase in
the number of pancreatectomies, major complications, and
readmission rates failed to reach statistical significance.
4.2. Impact of Changing Culture onNonparticipating Surgeons.
In order to validate the hypothesis that changes after ERAS
protocol implementation on this closed, surgical oncology
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Table 4: ERAS versus non-ERAS (control) for test surgeon, 2013–2015.
Factor ERAS% (number) No ERAS% (number) 𝑝 value OR 𝑝 value
Gender
Male 46.0 (40) 46.7 (43) 0.92
Female 54.0 (47) 53.3 (49)
Age
Median 62 (20–93) 63 (28–88) 0.41
Mean 61.4 (13.9) 63.1 (13.9)
Race
White 62.1 (54) 60.9 (56)
0.95Black 34.5 (30) 34.8 (32)
Other 3.4 (3) 4.3 (4)
Diagnosis
Gastric cancer 4.8 (4) 12.0 (11)
0.35
Small bowel cancer 8.4 (7) 5.4 (5)
Colorectal cancer 24.1 (20) 26.1 (24)
Pancreatic cancer 21.7 (18) 13.0 (12)
Liver malignancies 12.1 (10) 15.2 (14)
Other abdominal 28.9 (24) 28.3 (26)
Charlson index
0–2 43.7 (38) 47.8 (44)
0.463–5 36.8 (32) 28.3 (26)
>5 19.5 (17) 23.9 (22)
Surgery
Pancreatectomy 27.6 (24) 14.1 (13)
0.064
2.07 0.069
Colectomy 12.6 (11) 12.0 (11) Referent Referent
Hepatic resection 12.6 (11) 20.7 (19) 1.30 0.58
Gastrectomy 4.6 (4) 12.0 (11) 1.07 0.91
Intestinal resection 16.1 (14) 21.7 (20) 1.23 0.64
Other abdominal 26.4 (23) 19.5 (18) 1.63 0.23
LOS
Median 5 (1–39) 6 (1–55) 0.024
Mean 6.2 (4.9) 9.6 (9.3)
Complications
Grade 0-I 67.8 (59) 54.4 (50) 0.064
Grade II–V 32.2 (28) 42.6 (42)
Cost
Median 18,716 (7,937–93,804) 24,395 (6,052–174,536) 0.029
Mean 21,674 (12,118) 30,380 (25,723)
Readmission 11.5 (10) 21.4 (19) 0.076
Mortality 0 (0) 3.3 (3) 0.044
unit were different from the changes in unit culture and
expectations, we examined the nontest physicians’ patients
before and after the educational programs and ERAS imple-
mentation. We found that the patients were similar in gen-
der, age, race, diagnosis, comorbidities, surgical procedures,
postoperative LOS, complications,median costs, readmission
rate, and mortality. Table 5 shows that the variables before
and after the implementation of ERAS in nonparticipating
physicians are remarkably similar. This implies that the
changes in the patient outcomes are not dependent upon the
cultural shifts in patterns of care of the surgical unit.
5. Conclusion
ERAS is amultimodal, evidence-based perioperative pathway
that has been demonstrated to decrease the cost, LOS, mor-
bidity, and mortality after major surgical interventions. Sur-
gical literature is replete with data describing the outcomes of
ERAS implementation in defined patient populations such as
colorectal, hepatopancreatobiliary, esophageal, gynecologic,
gastric, acute-care, or urologic surgeries [4, 14, 15, 19, 25,
28, 29]. However, there is a lack of data on the applicability
of ERAS to real-world diverse surgical practices. It is also
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Table 5: Control providers before and after ERAS implementation, 2013–2015.
Factor Pre-ERAS Post-ERAS 𝑝 value
Gender
Male 51.3 (61) 47.9 (46) 0.63
Female 48.7 (58) 52.1 (50)
Age
Median 63 (28–88) 65 (22–86) 0.78
Mean 62.9 (12.1) 62.4 (12.2)
Race
White 59.7 (71) 57.3 (55)
0.93Black 37.0 (44) 39.6 (38)
Other 3.4 (4) 3.1 (3)
Diagnosis
Gastric cancer 2.5 (3) 7.7 (7)
0.43
Small bowel cancer 7.6 (9) 4.4 (4)
Colorectal cancer 33.6 (40) 26.4 (24)
Pancreatic cancer 14.3 (17) 15.4 (14)
Liver malignancies 6.7 (8) 7.7 (7)
Other abdominal 35.3 (42) 38.5 (35)
Charlson index
0–2 34.5 (41) 37.5 (36)
0.363–5 49.6 (59) 40.6 (39)
>5 16.0 (19) 21.9 (21)
Surgery
Pancreatectomy 19.3 (23) 24.0 (23)
0.51
Colectomy 21.9 (26) 19.8 (19)
Hepatic resection 11.8 (14) 10.4 (10)
Gastrectomy 1.7 (2) 6.3 (6)
Intestinal resection 19.3 (23) 15.6 (15)
Other abdominal 26.1 (31) 24.0 (23)
LOS
Median 6 (1–45) 5 (1–44) 0.51
Mean 7.6 (5.9) 7.1 (6.3)
Complications
Grade 0-I 61.3 (73) 69.8 (67) 0.20
Grade II–V 38.7 (46) 30.2 (29)
Cost
Median 21,109 (6,412–111,409) 20,157 (6,951–135,993) 0.40
Mean 23,235 (13,960) 25,210 (19,893)
Readmission 15.1 (18) 15.1 (14) 0.99
Mortality 2.5 (3) 3.1 (3) 0.79
unclear whether the differences in outcomes are attributable
to the changes in practice or changes in expectations.
In this study, we found that the principles of ERAS could
be applied to various abdominal procedures by utilizing a
single perioperative pathway. The utilization of this general
ERAS pathway for abdominal procedures, including pancre-
atectomy, hepatectomy, colectomy, gastrectomy, and small
bowel resection, resulted in significant decrease in LOS, cost,
and mortality rates. Despite extensive training to nursing
staffs of the single and closed surgical oncology unit, there
were no changes in outcomes in the unit of non-ERAS
(control) patients.
To have maximal impact of ERAS protocol, it must be
translatable into settings in which most surgeons practice.
Majority of general surgeons do not focus on a specific
surgery but rather treat patients with a variety of surgical
conditions. In this setting, multiple or individual ERAS
pathways for each procedure type may not be practical.
Our data also suggested that a more general periopera-
tive pathway would suffice to encompass the principles of
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Table 6: Differences in LOS and cost by procedure type in ERAS versus non-ERAS groups, 2013–2015.
Surgery type Mean postop LOS Mean total cost
ERAS Non-ERAS 𝑇 score 𝑝 value ERAS Non-ERAS 𝑇 score 𝑝 value
Pancreatectomy 9.0 9.9 −0.53 0.60 $30,524 $32,787 −0.58 0.57
Other abdominal 5.0 6.4 −1.3 0.21 $17,713 $21,268 −1.3 0.19
Colectomy 5.3 7.6 −1.9 0.059 $20,733 $24,219 −0.91 0.37
Intestinal resection 4.8 7.5 −3.5 0.001 $18,391 $20,892 −0.90 0.37
Hepatic resection 3.8 7.4 −2.9 0.0057 $16,770 $27,213 −3.2 0.0030
Gastrectomy 5.8 13.1 −2.1 0.045 $18,915 $40,853 −2.2 0.043
ERAS. The benefits analyzed by utilizing a single set of
preoperative instructions, generalized recommendations for
perioperative nutrition, and a single postoperative order set
were similar to those reported from more focused programs
[8, 14, 15, 19, 27, 28, 30]. The improvements in outcome
measures were most marked for procedures that did not have
existing postoperative order sets such as other abdominal,
hepatectomy, and gastrectomy compared to pancreatectomy
and colectomy procedures that had preexisting postoperative
pathways (Table 6).
ERAS perioperative pathways have been demonstrated to
decrease the cost of care.WhenERAS andnon-ERASpatients
were compared in this series, we found a marked decrease
in the costs of approximately $2,500 per patient. Decrease in
costs wasmore in the case of the test surgeon’s patients, which
was >$5,000 per patient. Although these differences did not
reach statistical significance, they are in linewith those results
reported by other investigators. Joliat et al. noted a decrease of
8000 Euros in costs for patients undergoing pancreatectomy
procedure after ERAS implementation [13]. Green reported
a $4,800 decrease in costs for patients undergoing colon
surgery [31]. Similar results have been also reported in
both North American and European series for gynecologic,
bariatric, general, and vascular surgeries [32]. Decreasing
costs are likely to result from the shorter LOS and fewer
complications.
Evidence on decreased LOS and cost due to the imple-
mentation of ERAS protocol after major surgical interven-
tions is compelling. In this study, we noted amarked decrease
in LOS approximately by three days. Recent meta-analyses
have demonstrated a similar decrease in LOS by 2-3 days
after colectomy, 2.5 days after hepatic resection, 1.5 days
after gynecologic surgery, and 2–6 days after pancreatectomy
surgeries [14, 17, 29].
When implementing an ERAS protocol or any other qual-
ity program, it is imperative to examine the pre- and post-
ERAS implementation data to ensure that any unintended
consequences are appropriately detected, and the hypothe-
sized improvements actually occurred in patient outcomes.
In this study, we also found a decreased risk of mortality rate
in the ERAS cohort (0 versus 3%, 𝑝 = 0.033). Similarly, we
found no increase in the readmission rate, which suggested
a trend of potential decrease. These findings were in contrast
to most of the reports in which ERAS neither increased nor
decreased the readmission or mortality rates [17, 18, 33, 34].
The benefits of ERAS cannot be solely attributed to the
changes in the provider’s education and recovery expecta-
tions. In this study, we found that the improvements in cost,
LOS, mortality, and readmission rate were confined to the
patients enrolled only in the ERAS protocol. This occurred
even though all patients emanated from a single specialty
clinic and managed in a single closed surgical unit with the
same residents, nursing staffs, attending physicians, and allied
health staffs, all of whom were educated regarding the ERAS
protocol. This suggests the details matter and that is not
ethereal shifts in expectations the drive improvement. This
is consistent with several prospective randomized controlled
trials examining the impact of ERAS protocol implementa-
tion on patient outcomes [14, 35–37]. In addition, several
investigators have also reported on the improved outcomes
having higher compliance with ERAS components [5, 37, 38].
In conclusion, ERAS perioperative protocols improve the
patient outcomes. Our data collected in context with the
current literature demonstrate that the ERASprotocols can be
implemented on awide range of patients undergoing complex
abdominal surgeries. Such protocols need not be procedure
specific but should incorporate the general principles of
ERAS in a single perioperative program. The benefits from
such programs include decreased LOS, cost, and mortality
rates. It is our hope that these data would demystify the ERAS
implementation for the general surgeons and promote its
adoption in mixed surgical practices.
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